drugset / Trial / NCT00414310

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

NCT00414310

Phase 2 Completed 153 enrolled M.D. Anderson Cancer Center Eisai Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find out if decitabine, given with or without valproic acid, can help to control AML or MDS. The safety of both treatments will also be studied.

Timeline

Start
2006-12
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 20 mg/m2 Intravenous
Subject Valproic Acid Small molecule 50 mg/kg Oral